Shots:

• The US FDA has approved Procysbi for adults and children one year of age and older living with nephropathic cystinosis
• Procysbi (cysteamine bitartrate) is a delayed-release capsules and delayed-release oral granules also a cystine-depleting agent indicated to treat nephropathic cystinosis in adults and pediatric patients 1 year of age and older
• Procysbi will continue to be available in 25 mg and 75 mg strengths while the 75mg and 300mg is expected to be available in H1’20

Click here to­ read full press release/ article | Ref:  Horizon Therapeutics | Image: Horizon Therapeutics